Clinical Trial Update: Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating clofarabine, cyclophosphamide, and etoposide for minimal residual disease-positive acute leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Clofarabine (clofarabine)
• Etoposide (Etoposide)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Status: WITHDRAWN